CR20160184A - Piperidil-etil-pirimidina sustituido como inhibidor de ghrelin o-acil transferasa - Google Patents

Piperidil-etil-pirimidina sustituido como inhibidor de ghrelin o-acil transferasa

Info

Publication number
CR20160184A
CR20160184A CR20160184A CR20160184A CR20160184A CR 20160184 A CR20160184 A CR 20160184A CR 20160184 A CR20160184 A CR 20160184A CR 20160184 A CR20160184 A CR 20160184A CR 20160184 A CR20160184 A CR 20160184A
Authority
CR
Costa Rica
Prior art keywords
transferasa
piperidil
etil
acil
ghrelin
Prior art date
Application number
CR20160184A
Other languages
English (en)
Inventor
Maria Angeles Martinez-Grau
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20160184A publication Critical patent/CR20160184A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a inhibidores de GOAT novedosos y sus sales y composiciones farmacéuticas de los mismos.
CR20160184A 2013-11-14 2016-04-21 Piperidil-etil-pirimidina sustituido como inhibidor de ghrelin o-acil transferasa CR20160184A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382460 2013-11-14
PCT/US2014/064202 WO2015073281A1 (en) 2013-11-14 2014-11-06 Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor

Publications (1)

Publication Number Publication Date
CR20160184A true CR20160184A (es) 2016-06-17

Family

ID=49622771

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160184A CR20160184A (es) 2013-11-14 2016-04-21 Piperidil-etil-pirimidina sustituido como inhibidor de ghrelin o-acil transferasa

Country Status (39)

Country Link
US (1) US9035051B1 (es)
EP (1) EP3068775B1 (es)
JP (1) JP6159484B2 (es)
KR (1) KR101739243B1 (es)
CN (1) CN105636948B (es)
AP (1) AP2016009189A0 (es)
AR (1) AR098274A1 (es)
AU (1) AU2014348967B2 (es)
BR (1) BR112016009488B1 (es)
CA (1) CA2926224C (es)
CL (1) CL2016001023A1 (es)
CR (1) CR20160184A (es)
CY (1) CY1119489T1 (es)
DK (1) DK3068775T3 (es)
DO (1) DOP2016000070A (es)
EA (1) EA028550B1 (es)
ES (1) ES2647790T3 (es)
HR (1) HRP20171648T1 (es)
HU (1) HUE035590T2 (es)
IL (1) IL244856A (es)
JO (1) JO3302B1 (es)
LT (1) LT3068775T (es)
MA (1) MA39025B1 (es)
ME (1) ME02841B (es)
MX (1) MX2016006223A (es)
NO (1) NO3068775T3 (es)
NZ (1) NZ718373A (es)
PE (1) PE20160609A1 (es)
PH (1) PH12016500895A1 (es)
PL (1) PL3068775T3 (es)
PT (1) PT3068775T (es)
RS (1) RS56533B1 (es)
SG (1) SG11201602953YA (es)
SI (1) SI3068775T1 (es)
TN (1) TN2016000145A1 (es)
TW (1) TWI538677B (es)
UA (1) UA118034C2 (es)
WO (1) WO2015073281A1 (es)
ZA (1) ZA201602202B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104672A1 (es) * 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
AR104673A1 (es) * 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
RS61937B1 (sr) 2016-08-05 2021-07-30 Boehringer Ingelheim Int Oksadiazolopiridin derivati za primenu kao inhibitori grelin o-acil transferaze (goat)
CN106478519B (zh) * 2016-10-10 2018-12-11 上海再启生物技术有限公司 一种2-甲基-4-氨基-6-氯嘧啶的制备方法
MX2020008116A (es) 2018-02-02 2020-09-25 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat).
JOP20200187A1 (ar) * 2018-02-02 2020-07-29 Boehringer Ingelheim Int مشتقات ترايازولو بيريميدين للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat)
CN111655700B (zh) 2018-02-02 2023-07-18 勃林格殷格翰国际有限公司 作为饥饿素o-酰基转移酶(goat)抑制剂的噁二唑并吡啶衍生物
CN111630055B (zh) 2018-02-02 2023-07-14 勃林格殷格翰国际有限公司 用作饥饿素o-酰基转移酶(goat)抑制剂的吡唑取代的和吲唑取代的噁二唑并吡啶衍生物
CN108610337A (zh) * 2018-05-30 2018-10-02 王丽萍 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用
CN108516971A (zh) * 2018-05-30 2018-09-11 王丽萍 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用
CN108774221A (zh) * 2018-05-30 2018-11-09 王丽萍 一种goat抑制剂及其在肥胖和糖尿病中的应用
CN108558849A (zh) * 2018-05-30 2018-09-21 王丽萍 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用
CN108558852A (zh) * 2018-05-30 2018-09-21 王丽萍 一种goat抑制剂及其在肥胖和糖尿病中的应用
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
EP4153599B1 (en) 2020-05-22 2024-03-13 Boehringer Ingelheim International GmbH Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
PL4153600T3 (pl) 2020-05-22 2024-12-16 Boehringer Ingelheim International Gmbh Sposób ciągły wytwarzania 7-amino-5-metylo-[1,2,5]oksadiazolo[3,4- b]pirydynokarboksylanu alkilu

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1268449A4 (en) * 2000-03-23 2004-09-15 Merck & Co Inc SUBSTITUTED PIPERIDINE AS MELANOCORTIN RECEPTOR AGONISTS
WO2005026211A2 (en) 2003-09-05 2005-03-24 Eli Lilly And Company Anti-ghrelin antibodies
EP1776386A1 (en) 2004-07-14 2007-04-25 Eli Lilly And Company Anti-ghrelin antibodies
EP1814916A2 (en) 2004-11-15 2007-08-08 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
US7479271B2 (en) 2005-02-23 2009-01-20 Eli Lilly And Company Humanized anti-ghrelin antibodies
US7723342B2 (en) * 2005-05-17 2010-05-25 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
CN101175759A (zh) * 2005-05-17 2008-05-07 先灵公司 作为治疗血脂异常的烟酸受体激动剂的杂环化合物
WO2007079239A2 (en) * 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
KR20100134680A (ko) * 2008-03-20 2010-12-23 포레스트 래보러토리즈 홀딩스 리미티드 스테아로일-coa 불포화효소의 저해물질로서 신규한 피페리딘 유도체
AR091516A1 (es) * 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida

Also Published As

Publication number Publication date
TW201529073A (zh) 2015-08-01
ZA201602202B (en) 2019-10-30
AR098274A1 (es) 2016-05-18
BR112016009488A8 (pt) 2018-01-30
CN105636948B (zh) 2017-10-24
SI3068775T1 (sl) 2017-10-30
HK1222860A1 (en) 2017-07-14
WO2015073281A1 (en) 2015-05-21
SG11201602953YA (en) 2016-05-30
JO3302B1 (ar) 2018-09-16
EP3068775B1 (en) 2017-09-06
IL244856A0 (en) 2016-05-31
CL2016001023A1 (es) 2016-11-18
CA2926224C (en) 2017-05-02
HRP20171648T1 (hr) 2017-12-15
LT3068775T (lt) 2017-11-27
RS56533B1 (sr) 2018-02-28
KR20160068926A (ko) 2016-06-15
TN2016000145A1 (en) 2017-10-06
EA028550B1 (ru) 2017-11-30
US9035051B1 (en) 2015-05-19
EA201690764A1 (ru) 2016-07-29
CN105636948A (zh) 2016-06-01
CY1119489T1 (el) 2018-03-07
MA39025B1 (fr) 2018-05-31
ME02841B (me) 2018-01-20
NO3068775T3 (es) 2018-02-03
TWI538677B (zh) 2016-06-21
MX2016006223A (es) 2016-08-08
JP2016537371A (ja) 2016-12-01
EP3068775A1 (en) 2016-09-21
PT3068775T (pt) 2017-11-20
MA39025A1 (fr) 2017-05-31
US20150133474A1 (en) 2015-05-14
JP6159484B2 (ja) 2017-07-05
ES2647790T3 (es) 2017-12-26
AU2014348967A1 (en) 2016-04-28
DOP2016000070A (es) 2016-05-30
BR112016009488B1 (pt) 2021-01-19
PL3068775T3 (pl) 2018-01-31
IL244856A (en) 2017-07-31
AP2016009189A0 (en) 2016-05-31
HUE035590T2 (en) 2018-05-28
AU2014348967B2 (en) 2017-05-04
UA118034C2 (uk) 2018-11-12
PH12016500895B1 (en) 2016-06-20
CA2926224A1 (en) 2015-05-21
PH12016500895A1 (en) 2016-06-20
KR101739243B1 (ko) 2017-05-23
PE20160609A1 (es) 2016-07-03
DK3068775T3 (en) 2017-10-23
NZ718373A (en) 2017-12-22

Similar Documents

Publication Publication Date Title
UY4175Q (es) Reloj pulsera
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
ES2530968T3 (es) Pirrolobenzodiazepinas y conjugados de las mismas
CR20140464A (es) Compuestos de heterociclilo
CR20150507A (es) Inhibidores de histona desmetilasas
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
GEAP201814347A (en) Substituted dihydroisoquinoline compounds
HUE046273T2 (hu) Ciklopropilaminok mint LSD1 inhibitorok
HUE045725T2 (hu) Ciklopropilaminok mint LSD1 inhibitorok
CR20150061A (es) Compuesto de pirazolopirimidinas
HUE043440T2 (hu) Policiklusos amidszármazékok mint CDK9 inhibitorok
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
LT2895484T (lt) Gliukozilceramido sintazės inhibitoriai
EP3985003C0 (en) DNA-PK INHIBITORS
UY34763A (es) Inhibidores de la agregación plaquetaria
CO7111315A2 (es) Dihidrato de un compuesto de benzotiofeno o de una de sus sales y proceso para su producción
PH12016500895A1 (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
BR112015003294A2 (pt) caldeira de armazenamento
UY34666A (es) Inhibidores de quinasa a base de ariléter
ECSP14013305A (es) Moduladores selectivos del receptor andrógeno
MX2017007377A (es) Compuestos organicos.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
UY34631A (es) Formulación de doxilamina y piridoxina y/o sus metabolitos o sales
MX2015007608A (es) Metodos y composiciones para inhibir cnksr1.